Supervisor : Dr David Kryza Dr Clément Morgat
Title : new radiopharmaceuticals for targeted radionuclide therapy
Keywords: radiopharmaceuticals, cancer, imaging, therapy, in vivo studies
Starting date: sept/oct-23
Laboratory: the LAGEPP is a research laboratory of the University Lyon 1 and the French National Institute for Scientific research (CNRS UMR 5007). It develops multidisciplinary research in chemical engineering, pharmaceutical engineering and biochemical processes. The imaging plat-form Imthernat has a strong expertise notably for in vivo biodistribution and efficacy studies in mice models using SPECT/CT, PET/CT and Cerenkov imaging.
The post doctoral researcher will take part of a French jointed project aiming at evaluating novel radiopharmaceuticals for imaging and therapy of selected cancers including hard-to-treat cancer models (triple negative breast cancer, glioblastoma, pancreatic adenocarcinoma, etc)
Principal activities
- Generation and follow-up of xenografted mice
- Radiolabeling
- In vivo imaging and biodistribution
- Image analysis and data processing
Required skills
- Use of preclinical cancer models
- Cell culture
- In vivo animal experience
Soft skills
- Motivated,
- Enthusiastic
- Strong commitment for the research project
- Good communication, presentation and writing skills
- Able to lead work
- Good sense for initiative and quality
- Team player
Language: English is required. French is optional
The application must include
- CV
- Motivation letter
- Two reference letters
- Academic works that you would like to be considered in the assessment
Contacts: david.kryza@univ-lyon1.fr; clement.morgat@u-bordeaux.fr